David Luke

Strategic Advisor @Arch Biopartners Inc Arch Tsxv Achff Otcqb

Charlestown, RI, US
MOBILE NUMBERS
+91 *********19

Signup · Get unlimited contacts

WORK HISTORY

Mar 2020 — Present

Strategic Advisor @Arch Biopartners Inc Arch Tsxv Achff Otcqb

View department →

Toronto, ON, CA

Working alongside Richard Muruve, CEO and Daniel Muruve, MD and CMO at Arch Biopartners, we are developing the regulatory strategy and clinical development of the novel immunomodulator, LSALT peptide for the prevention of COVID-19-related complications, including ARDS, AKI, cardiomyopathies, acute liver injury, coagulopathies, and all-cause mortality. We have developed a Phase 2 protocol (NCT04••••57) and the associated ICF and IB, for submission and acknowledgment of a CTA in Canada and IND in the US - all within 3 months. The study successfully completed in April 2021. We are now initiating a study in preventing acute kidney injury following cardiac surgery (NCT05••••32) and entered our first 2 patients in March 2024.

EDUCATION

N/A

University of Toronto

Bachelor of Science

N/A

University of Toronto

BSc Pharmacy, Pharmacy

N/A

University of the Sciences in Philadelphia

PharmD, Clinical Pharmacy

N/A

University of Toronto

BScPhm, Pharmacy

N/A

University of Minnesota

Fellow, Infectious Diseases and Nephrology

N/A

University of the Sciences in Philadelphia

Doctor of Pharmacy, Pharmacy

N/A

York University

Bachelor of Arts

N/A

University of Minnesota

Fellowship, Infectious Diseases and Nephrology

SKILLS

PharmacyPharmaceuticsMedical AffairsClinical TrialsPharmacologyRegulatory SubmissionsCompetitive IntelligenceLeadershipCardiologyManaged CareClinical DevelopmentInfectious DiseasesResearchMedical DevicesClinical ResearchPharmacovigilanceVaccinesStrategyDiabetesSales EffectivenessDrug DevelopmentCancerGcpOncologyUrologyInformaticsProtocolHospitalsBiotechnologyPain ManagementRheumatologyProduct LaunchMedical WritingNephrologyPsychiatryEndocrinologyDermatologyImmunologyPharmaceuticalsGastroenterology

ABOUT DAVID LUKE

I have extensive experience leading and executing development plans and studies for all phases of drug development from preclinical through Phase 3, including 25+ INDs, 18 US and global regulatory submissions, 16 product launches, and life cycle management following these launches. I have broad experience managing multi-million dollar budgets, optimizing timelines and resources, and product strategy plans. Main therapeutic areas of expertise are infectious diseases, nephrology, neurosciences, diabetes, pulmonary, immunology, and pharmacokinetics/pharmacology. I am a pharmaceutical research consultant currently working closely with large PhRMA and biotech companies in infectious diseases, nephrology, neurosciences, immunology, and diabetes based in the US, Canada, and globally - D••••••••@gmail.com

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

David Luke — Strategic Advisor at Arch Biopartners Inc Arch Tsxv Achff Otcqb in Charlestown, RI, US | Unifers